Clinical trial
A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose, Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Pain and Opioid-Induced Nausea and Vomiting (OINV)
NCT02462811 is registered in ClinicalTrials.gov with Joseph Hazelton as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose, Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Pain and Opioid-Induced Nausea and Vomiting (OINV)
- Lead sponsor
- Joseph Hazelton
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- September 30, 2014
- Completion date
- August 31, 2015
- Enrollment
- 552 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.